The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx‘s pioneering business model to accelerate the development of drug candidates in oncology and immune-inflammatory diseases and improve global access to innovative medicines.
What were the terms of the agreement?
Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization. Aurigene will lead drug discovery and pre-clinical development efforts, while EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
The parties would share both funding for the discovery and development of the programs and financials resulting from the commercialization of any eventual drug candidates.
What were the executives’ thoughts on the partnership?
“This agreement with EQRx further validates Aurigene’s proven expertise in discovery and preclinical development of novel therapeutics and moves Aurigene forward into building a global oncology franchise participating in the end-to-end value chain. We are excited to collaborate with EQRx and contribute to developing and delivering innovative medicines to patients at more affordable prices,” said Murali Ramachandra, Ph.D., CEO of Aurigene.
“We are excited to partner with Aurigene to expand our pipeline and accelerate the discovery of next-gen therapeutics,” said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx.
“Our combined efforts will focus on high-impact therapeutic targets across oncology and immune-inflammatory diseases. We believe these programs hold the potential to create vital treatments for patients and drive meaningful savings for healthcare systems worldwide.”